Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Cancer

Treatments: Combination Product: Subcutaneous nivolumab combined with hyaluronidase; Drug: Nivolumab

Study type: Observational

Funder types: Industry

Identifiers

NCT07636863

CA209-1582

Details and patient eligibility

About

This study will review medical records of adults with cancer who received nivolumab either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection in community oncology clinics in the United States. The study will describe who receives each type of treatment, how the treatments are used, and selected safety events such as reactions at the injection or infusion site and infections.

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Are ≥ 18 years of age at the index date

• Have a confirmed cancer diagnosis

• Received one of the following treatments:

  • Intravenous (IV) nivolumab
  • Subcutaneous (SC) nivolumab + hyaluronidase

Exclusion criteria

• Currently receiving a clinical trial therapy at index
• Currently receiving treatment for another active concurrent primary cancer diagnosis
• Received IV nivolumab or SC nivolumab + hyaluronidase off-label

Trial design

200 participants in 2 patient groups

IV Nivolumab

Description:

Participants who receive intravenous (IV) nivolumab in community oncology settings.

Treatment:

Drug: Nivolumab

SC Nivolumab + Hyaluronidase

Description:

Participants who receive subcutaneous (SC) nivolumab combined with hyaluronidase

Treatment:

Combination Product: Subcutaneous nivolumab combined with hyaluronidase